Vitamin D Treatment in End-Stage Kidney Disease

Introduction to Vitamin D Therapy

• The American College of Physicians recommends vitamin D treatment for patients with end-stage kidney disease, including calcimimetics, calcitriol, or vitamin D analogues, with selection based on serum calcium, phosphorus, and PTH levels 1

Types of Vitamin D Therapy

• The National Kidney Foundation recommends supplementation with ergocalciferol or cholecalciferol for patients with vitamin D deficiency 2
• Active vitamin D compounds, such as calcitriol 4 and doxercalciferol 4, are recommended for patients with elevated PTH levels

Indications for Active Vitamin D Therapy

• The American Journal of Kidney Diseases recommends treatment with active vitamin D sterols when intact PTH levels exceed 300 pg/mL in dialysis patients 3
• Treatment should only be initiated when serum corrected total calcium is less than 9.5 mg/dL and serum phosphorus is less than 4.6 mg/dL 3

Dosing Guidelines

• The American Journal of Kidney Diseases recommends intravenous administration of calcitriol for hemodialysis patients, as it is more effective than daily oral calcitriol in lowering serum PTH levels 3
• For peritoneal dialysis patients, oral dosing options include calcitriol (0.5 to 1.0 μg, 2-3 times weekly, or 0.25 μg daily) and doxercalciferol (2.5 to 5.0 μg, 2-3 times weekly) 3

Monitoring Parameters

• The American Journal of Kidney Diseases recommends monitoring calcium and phosphorus every 2 weeks for 1 month after initiation or dose change, then monthly 3
• PTH should be measured monthly for at least 3 months, then every 3 months once target levels are achieved, with a target PTH range of 150-300 pg/mL for dialysis patients 3

Dose Adjustments

• If PTH falls below target range, therapy should be held until PTH rises above target, then resumed at half the previous dose 3
• If calcium exceeds 9.5 mg/dL, therapy should be held until calcium normalizes, then resumed at half the previous dose 3

Newer vs. Conventional Vitamin D Analogues

• Selective VDR activators, such as paricalcitol and doxercalciferol, may have advantages over conventional therapy, including less calcemic and phosphatemic effects while maintaining PTH suppression 4

Nutritional Vitamin D Supplementation

• The American Journal of Kidney Diseases recommends evaluating patients with ESKD for vitamin D deficiency and considering higher doses of supplementation (4,000 IU/day) than the general population 5

Dialysate Calcium Considerations

• The American Journal of Kidney Diseases recommends a dialysate calcium concentration of 2.5 mEq/L (1.25 mmol/L) to balance the need for PTH control while minimizing the risk of hypercalcemia 3

Potential Adverse Effects and Cautions

• Hypercalcemia is a common side effect of active vitamin D therapy, and hyperphosphatemia can occur with all vitamin D sterols 4
• Adynamic bone disease risk increases when PTH is suppressed below 150 pg/mL, and vascular calcification may be increased in patients with biochemical features consistent with adynamic bone 6